Business Context and Reporting Period
This Form 8-K was filed by NAYA Biosciences, Inc. (formerly INVO Bioscience, Inc.) on November 8, 2024, reporting an event dated November 4, 2024. The company is a Nevada corporation with its principal executive offices in Sarasota, Florida, and its common stock trades on The Nasdaq Capital Market under the symbol "NAYA."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory compliance status rather than financial performance.
Material Changes
The primary material event is the resolution of a listing deficiency. On November 4, 2024, the Company received notice from Nasdaq confirming compliance with Listing Rule 5550(b)(1) (the "Equity Rule"). This compliance satisfies the requirements set forth in a Nasdaq Hearing Panel decision dated June 18, 2024, as amended.
Outlook, Risks, and Management Commentary
As a condition of the compliance determination, the Company is subject to a mandatory panel monitor for a period of one year from the date of the notification. No specific financial guidance, risk factors, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the Company's continued compliance with Nasdaq Listing Rule 5550(b)(1) over the upcoming 12-month monitoring period.
- Confirm the official name change from INVO Bioscience, Inc. to NAYA Biosciences, Inc. in market data systems.
- Review the June 18, 2024, Nasdaq Hearing Panel decision to understand the specific deficiencies previously cited.